Novelix Pharmaceuticals Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Novelix Pharmaceuticals Ltd is ₹ 54 as of 05 May 15:30 . The p/e ratio of Novelix Pharmaceuticals Ltd changed from 0 to 0 over 4 quarters. This represents a CAGR of 0.0% The p/e ratio of Sanofi India Ltd changed from 30.8 to 0 over 4 quarters. This represents a CAGR of -100.00% The market cap of Novelix Pharmaceuticals Ltd changed from ₹ 5.48 crore to ₹ 7.2 crore over 2 quarters. This represents a CAGR of 72.63% The market cap of Sanofi India Ltd changed from ₹ 18578 crore to ₹ 0 crore over 4 quarters. This represents a CAGR of -100.00% The Revenue of Novelix Pharmaceuticals Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Novelix Pharmaceuticals Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Novelix Pharmaceuticals Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Novelix Pharmaceuticals Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Novelix Pharmaceuticals Ltd

Trimurthi Limited was formerly incorporated on December 13, 1994 with the name Trimurthi Securities Ltd. The name of the Company thereafter got changed from Trimurthi Securities Ltd to Trimurthi Drugs & Pharmaceuticals Ltd. In September 2006, as per the Scheme of Arrangement, the erstwhile Trimurthi Drugs & Pharmaceuticals Ltd amalgamated with the Company.
Also, the name of the Company was changed to Trimurthi Drugs & Pharmaceuticals Ltd and again to Trimurthi Limited in May, 2016. Initially, the company was engaged in finance and investments in securities.
They ceased their operations due to the high volatility in the markets and voluntarily got de-registered as Non-Banking financial company.
Thereafter, the company explored the possibilities of entering into pharmaceutical and drug industry by way of diversification.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Novelix Pharmaceuticals Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Novelix Pharmaceuticals Ltd or Sanofi India Ltd?

Market cap of Novelix Pharmaceuticals Ltd is 58 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Novelix Pharmaceuticals Ltd and Sanofi India Ltd?

The stock performance of Novelix Pharmaceuticals Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Novelix Pharmaceuticals Ltd and Sanofi India Ltd?

As of May 5, 2026, the Novelix Pharmaceuticals Ltd stock price is INR ₹40.5. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Novelix Pharmaceuticals Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Novelix Pharmaceuticals Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.